A healthy piglet protected by an immune shield, symbolizing enhanced vaccine efficacy against PRRSV.

Boosting Swine Health: Can This Saponin-Vaccine Combo Beat PRRSV?

Beau Callahan monogram
Beau Callahan in Health & Wellness November 2026 • 4 min read.

"New research explores how combining saponin quil A with a modified-live virus vaccine can revolutionize the fight against Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) in pigs."


Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is a major threat to the swine industry worldwide, leading to significant economic losses due to reproductive failures, respiratory diseases, and poor growth in pigs. Understanding how to combat this virus effectively is crucial for maintaining the health and productivity of swine populations.

Traditional vaccines have shown limitations in providing comprehensive protection against the diverse strains of PRRSV. Modified-live virus (MLV) vaccines, while commonly used, often elicit a delayed and weak immune response. This has prompted researchers to explore novel strategies to enhance vaccine efficacy and broaden the spectrum of protection.

Recent studies have focused on the potential of adjuvants—substances that boost the immune response—to improve the performance of PRRSV vaccines. Saponin quil A, a natural compound known for its immunostimulatory properties, has shown promise in upregulating key immune genes and cytokines. This article delves into a new study investigating the combined effects of quil A and a PRRSV-1 MLV vaccine, offering insights into a potential breakthrough in PRRSV prevention and control.

AI Search Multiple angles on this topic

PRRSV and the Case for Immune Stimulation

PRRSV suppresses innate immune responses in myeloid antigen-presenting cells, which can weaken and delay PRRSV-specific adaptive immunity and facilitate viral replication, pathogenesis, and persistent infection. The study titled “Saponin Quil A up-regulates type I interferon-regulated gene and type I and II interferon expressions” reports that Quil A can up-regulate interferon responses suppressed by PRRSV. Separately, the adjuvant review describes QS-21 as a potent saponin-based adjuvant and says saponin adjuvants can stimulate Th1 and cytotoxic T-cell responses.

A Disease Recognized in the Late 1980s

PRRS, caused by PRRSV, has been recognized as one of the most consequential infectious diseases of swine since the late 1980s. A 2024 comprehensive review surveys the disease’s history and economic and scientific importance. It also covers PRRSV’s viral structure and genetic diversity.

How Does Quil A Enhance Immunity Against PRRSV?

A healthy piglet protected by an immune shield, symbolizing enhanced vaccine efficacy against PRRSV.

A recent study published in Veterinary Immunology and Immunopathology explored the immunostimulatory effects of quil A when used in conjunction with a PRRSV-1 MLV vaccine. The research aimed to determine if quil A could enhance the cross-protective immunity of the vaccine against PRRSV-2 challenge. Twenty-four 4-week-old PRRSV-seronegative pigs were divided into four groups:

  • Group 1: Vaccinated with PRRSV-1 MLV vaccine.
  • Group 2: Vaccinated with PRRSV-1 MLV vaccine and injected with quil A.
  • Group 3: Injected with PRRSV-1 MLV vaccine solvent (challenge control).
  • Group 4: Strict control group (no treatment).
Groups 1-3 were challenged intranasally with PRRSV-2 at 28 days post-vaccination (dpv), and immune and clinical parameters were observed for 49 days.

AI Search Multiple angles on this topic

Limits of Existing Vaccine Protection

Commercially available PRRSV vaccines generally protect well against the vaccine strain, but offer limited protection against emerging strains. A 2025 report describes suboptimal immunogenicity and efficacy of existing vaccines as an obstacle to PRRSV control. A Quil A co-administration study enrolled 24 PRRSV-seronegative pigs aged four weeks, divided into four groups of six; the supplied study description does not report its efficacy results.

Fostera PRRS Meta-Analysis

A meta-analysis evaluated the modified live virus vaccine Fostera® PRRS against heterologous PRRSV strains. Vaccinated pigs had an average daily weight gain 38.52 g/d higher than non-vaccinates. Their mortality was 65% lower, with a relative risk of 0.35.

The study revealed significant benefits from the combined treatment:
  • Reduced Viremia: Group 1 pigs showed significantly reduced PRRSV viremia and fewer viremic pigs compared to Group 3.
  • Enhanced Gene Expression: Group 2 pigs exhibited increased mRNA expressions of interferon regulatory factor 3, 2'-5'-oligoadenylatesynthetase 1, osteopontin, IFNa, IFNẞ, IFNy, interleukin-2 (IL-2), IL-13, and tumor necrosis factor alpha compared to Group 1.
  • Clinical Improvements: Group 2 pigs also demonstrated reduced PRRSV viremia and fewer viremic pigs, suggesting a more robust immune response.

Why This Matters for Swine Health Management

This study highlights the potential of quil A as an effective immunostimulator to enhance cell-mediated immune defense against PRRSV. The findings suggest that combining quil A with PRRSV-1 MLV vaccine can significantly reduce viremia and improve clinical outcomes in pigs challenged with PRRSV-2. This approach offers a promising avenue for developing more effective strategies to combat PRRSV, safeguarding swine health and reducing economic losses in the swine industry.

AI Search Multiple angles on this topic

Evidence from Trials and Real-World Outcomes

A study described on October 24, 2025, set out to compare intranasal and intramuscular administration of a commercial PRRSV-2 modified-live vaccine in 3-day-old piglets challenged with a Thai HP-PRRSV strain. The supplied description gives the study’s aim but not its results. Separately, a July 2025 study reports using causal-inference methods to analyze real-world vaccination outcomes and provide evidence-based guidance for optimizing commercial swine vaccination protocols.

Toward Next-Generation PRRS Vaccines

A June 2024 review assesses the strengths and weaknesses of live attenuated and inactivated vaccines for PRRS prevention and management. Its stated aim is to help inspire innovative strategies and technologies for next-generation PRRS vaccines. Another description of the review says it updates knowledge of PRRS vaccines’ interactions with the host interferon system and other immunological aspects.

Herd-Level Costs and One Health Response

A challenge-model source reports that most pig herds in major producing countries are endemically infected with PRRSV. It describes reproductive failure in sows, respiratory signs in piglets, and deprivation of the immune system among impacts in affected herds. A December 2025 study proposes an integrated One Health framework for PRRSV surveillance and control, emphasizing genomic tools, systematic environmental monitoring, and collaboration across public health, veterinary, and environmental sectors.

How vaccine comparisons put the figures in context

  • 16.82; 1.36In the same comparison, the average maximum lung-lesion score was lower by 16.82 percentage points, and maximum serum viral load was lower by 1.36 log10 PRRSV RNA copies.[1]
  • 6.84 ± 0.23 log10 copies/μLIn another vaccine comparison, unvaccinated pigs had serum viral titers of 6.84 ± 0.23 log10 copies/µL at 4 days post-challenge, significantly higher than the MLV group.[2]
  • 0.74; 0.77; 0.76 kg/dayFor challenged vaccinated pigs in a separate comparison, average daily weight gain was 0.74 and 0.77 kg/day at the two reported challenge levels, close numerically to 0.76 kg/day in vaccinated, unchallenged pigs.[3]

What the immune and clinical measures establish

The combination’s reported reduction in viremia did not translate into better antibody measures, temperatures, clinical scores, or weight gain than vaccination alone. The evidence therefore points to a narrower improvement in measured virus circulation, rather than a demonstrated across-the-board clinical advantage.[4]

Quil A’s reported effects on interferon-related responses in infected blood cells provide a possible biological rationale for pairing it with vaccination, but that rationale is distinct from evidence of broader protection in pigs.[4]

How the vaccine evidence differs across comparisons

A separate recombinant adenovirus-vaccine description says Quil A was used as an adjuvant and that the animal experiments evaluated immunogenicity. Because this involved a different vaccine platform, it does not directly establish how Quil A performs with the PRRSV-1 MLV vaccine.[5]

MLV vaccines can replicate in the host and may be shed, and the cited discussion raises concerns about incomplete protection and safety. These concerns frame the trade-offs around MLV use; they do not show that Quil A resolves them.[6]

What remains unresolved about Quil A and MLV

  • Does the reduction in virus circulation with Quil A translate into meaningful clinical benefit, given that other measured clinical and antibody outcomes were not further improved over vaccination alone?[4]
  • Can Quil A address the safety concerns raised for replicating, potentially shedding MLV vaccines, or does it affect only immune responses and viral measures?[4] [6]

Sources

  1. The efficacy of a modified live virus vaccine Fostera® PRRS against heterologous strains of porcine reproductive and respiratory syndrome virus: A meta-analysis. (pubmed.ncbi.nlm.nih.gov)
  2. Evaluation of a type 2 modified live porcine reproductive and respiratory syndrome vaccine against heterologous challenge of a lineage 3 highly virulent isolate in pigs (pmc.ncbi.nlm.nih.gov)
  3. Examination of viraemia and clinical signs after challenge with a heterologous PRRSV strain in PRRS Type 2 MLV vaccinated pigs: A challenge-dose study (pmc.ncbi.nlm.nih.gov)
  4. Co-administration of saponin quil A and PRRSV-1 modified-live virus vaccine up-regulates gene expression of type I interferon-regulated gene, type I and II interferon, and inflammatory cytokines and r (pubmed.ncbi.nlm.nih.gov)
  5. www.jstage.jst.go.jp (www.jstage.jst.go.jp)
  6. Porcine Reproductive and Respiratory Syndrome Modified Live Virus Vaccine: A “Leaky” Vaccine with Debatable Efficacy and Safety (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), and why is it a concern for the swine industry?

Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is a major threat to the swine industry globally. It leads to significant economic losses due to reproductive failures, respiratory diseases, and poor growth in pigs. Therefore, effectively combating this virus is crucial for maintaining the health and productivity of swine populations. The limitations of traditional vaccines in providing comprehensive protection against the diverse strains of PRRSV, combined with the delayed and weak immune response elicited by modified-live virus (MLV) vaccines, have prompted researchers to explore novel strategies to enhance vaccine efficacy and broaden the spectrum of protection.

2

How does the combination of saponin quil A and a modified-live virus (MLV) vaccine work against PRRSV in pigs?

Saponin quil A acts as an immunostimulator when co-administered with a Porcine Reproductive and Respiratory Syndrome Virus (PRRSV)-1 modified-live virus (MLV) vaccine. This combination enhances the immune response, specifically the cell-mediated immune defense, against PRRSV. In a study, pigs vaccinated with the PRRSV-1 MLV vaccine and injected with quil A showed increased mRNA expressions of interferon regulatory factor 3, 2'-5'-oligoadenylatesynthetase 1, osteopontin, IFNa, IFNẞ, IFNy, interleukin-2 (IL-2), IL-13, and tumor necrosis factor alpha. These pigs also experienced reduced viremia and fewer viremic occurrences when challenged with PRRSV-2. This indicates a more robust immune response and improved clinical outcomes compared to using the vaccine alone.

3

What were the main findings of the study that examined the use of quil A with a PRRSV-1 MLV vaccine?

The study revealed that combining quil A with a Porcine Reproductive and Respiratory Syndrome Virus (PRRSV)-1 modified-live virus (MLV) vaccine led to several significant improvements. Pigs treated with both quil A and the vaccine demonstrated reduced PRRSV viremia and fewer instances of viremia. Furthermore, they exhibited enhanced gene expression of key immune components such as interferon regulatory factor 3, 2'-5'-oligoadenylatesynthetase 1, osteopontin, IFNa, IFNẞ, IFNy, interleukin-2 (IL-2), IL-13, and tumor necrosis factor alpha. These findings suggest that quil A effectively boosts the immune response induced by the PRRSV-1 MLV vaccine, leading to better protection against PRRSV-2.

4

Why is viremia reduction an important outcome in the context of PRRSV, and how did the study demonstrate this?

Viremia reduction is an important outcome because it indicates that the virus is less prevalent in the pig's system, reducing the severity and duration of the infection. The study showed that pigs vaccinated with Porcine Reproductive and Respiratory Syndrome Virus (PRRSV)-1 modified-live virus (MLV) vaccine and injected with quil A had significantly reduced viremia when challenged with PRRSV-2. This reduction in viremia, along with fewer viremic pigs, demonstrates that the combination of quil A and the vaccine enhances the immune response, effectively controlling the viral load and improving clinical outcomes.

5

Could the combined use of saponin quil A and a PRRSV-1 MLV vaccine transform swine health management, and what are the potential economic implications for the swine industry?

Yes, the combined use of saponin quil A and a Porcine Reproductive and Respiratory Syndrome Virus (PRRSV)-1 modified-live virus (MLV) vaccine has the potential to transform swine health management by providing a more effective strategy to combat PRRSV. The improved immune response and reduced viremia observed in the study suggest that this approach could significantly reduce the incidence and severity of PRRSV infections. The economic implications for the swine industry are substantial, as reducing PRRSV-related reproductive failures, respiratory diseases, and poor growth can lead to increased productivity, lower veterinary costs, and improved overall profitability. This advancement could provide a more sustainable and cost-effective solution for managing PRRSV, ultimately safeguarding the health and economic stability of the swine industry.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.